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MicroAbstract 
The sequencing of biologics used in metastatic colorectal cancer may impact outcomes. We analysed 
a multicentre registry to address a question that cannot be answered using current clinical trial data. 
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Specifically, we found that whether or not patients had received prior bevacizumab the impact of 
epidermal growth factor receptor antibodies in later lines of therapy was maintained.   
Clinical Practice Points 
- Bevacizumab and the epidermal growth factor receptor antibodies are biological therapies 
that improve survival in metastatic colorectal cancer. 
- Patients with left sided primary tumours that are RAS wild type are most likely to benefit 
from treatment with an epidermal growth factor receptor inhibitor (EGFRI), whereas there 
are no predictive biomarkers for bevacizumab. 
- Biologics are routinely combined with chemotherapy, but should not be used concurrently. 
- The optimal sequencing and timing of biologic use in metastatic colorectal cancer is 
unknown and a subject of ongoing debate. 
- In an analysis of a comprehensive clinical registry we have found no evidence that prior 
bevacizumab use impacts the activity of EGFRIs in later lines of therapy. 
- Whilst a shorter time gap (< 6 months) between bevacizumab and epidermal growth factor 
receptor antibodies did not affect EGFRI activity in left sided primary tumours, it was 
associated with a shorter progression free survival in right sided primary tumours. 
- When treating metastatic colorectal cancer, EGFRIs can be used after bevacizumab, in RAS 
wild type tumours, without their efficacy being compromised. 
- When treating RAS wild type right sided primary tumours in later lines our data support a 
better outcome if the EGFRI is commenced more than 6 months after ceasing bevacizumab, 
although this finding may be a result of confounding rather than reflecting any true biologic 
interaction.  
 
 
Abstract 
Background. The FIRE-3 study reported that first line FOLFIRI plus cetuximab versus FOLFIRI plus 
bevacizumab, resulted in similar progression free survival (PFS) but improved overall survival (OS). A 
potential explanation is that the initial biologic administered in metastatic colorectal cancer (mCRC) 
impacts later line efficacy of the other. We sought to test this hypothesis. 
Methods. We interrogated our mCRC registry (TRACC) regarding treatment and outcome data for 
RAS wild type patients receiving epidermal growth factor receptor antibodies (EGFRI) in second and 
subsequent lines. Survival outcomes from commencement of EGFRI were determined as a function 
of prior bevacizumab use and the period of time between ceasing bevacizumab and commencing 
EGFRI.  
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Results. Of 2061 patients, 222 eligible patients were identified, of whom 170 (77%) had received 
prior bevacizumab and 52 (23%) had not. PFS and OS from EGFRI commencement did not differ by 
prior bevacizumab use (median 3.8 V 4.2 months, HR 1.12. P=0.81 and 9.0 V 9.2 months HR 1.19. 
P=0.48 respectively) for the whole cohort or when analysed by side of primary tumour (left HR 1.07; 
p= 0.57; right HR 1.2; p= 0.52). PFS was significantly shorter in right sided primary tumours when the 
time between bevacizumab and EGFRI was < 6 versus > 6 months (median 2.2 V 6 months HR 2.23; 
p=0.01) but not in left sided (median 4.2 V 5.5 months; HR 1.12; P= 0.26) 
Conclusions. Prior bevacizumab had no impact on the activity of subsequent EGFRI. The apparent 
impact of time between biologics in right sided tumours may reflect patient selection. 
Keywords:  biologics; sequencing; timing; interaction; survival;  
 
Introduction: 
Colorectal cancer (CRC) is a major health burden in Australia and worldwide, being the second 
leading cause of cancer related deaths.
1
 In the treatment of metastatic colorectal cancer (mCRC), 
questions regarding optimal use of the available biologic options in the RAS wild type population 
have driven recent randomised studies comparing the sequence of epidermal growth factor receptor 
inhibiting antibodies; either cetuximab or panitumumab (EGFRI) and the anti-vascular endothelial 
growth factor (VEGF) antibody, bevacizumab.
2,3
 Such trials were conducted in the USA by the Cancer 
and Leukaemia Research Group (CALGB) and in Germany and Austria (FIRE-3). Patients were 
randomised to either biologic in the first line and thereafter,  whilst not mandated or planned in the 
study protocols, could at the investigators discretion cross over to the alternate biologic in second 
line..
2,3
 Whilst overall survival comparisons differed between these studies for the enrolled 
population, post hoc analyses defined a major impact of primary tumour side on survival 
outcomes.
4,5
 Specifically, adding an EGFRI to first line chemotherapy improves survival in patients 
with left sided RAS wild type tumours. In contrast, across all first line studies, patients with right 
sided tumours do not benefit from EGFRI therapy.
6
  
In the FIRE-3 study, the first to study biologic sequencing in RAS wild type metastatic colorectal 
cancer, the initial choice of biologic did not impact first line progression free survival (PFS), however 
improved overall survival (OS) was seen in patients randomised to initial cetuximab therapy.
3
 
Subsequently it was shown that the PFS for second line treatment with an EGFRI was lower than PFS 
for second line bevacizumab, suggesting the initial biologic use may impact response to later use of 
the alternate biologic.
7
 Whilst EGFRI have proven activity in second and later treatment lines, these 
studies were conducted in an era with no or limited prior use of bevacizumab.
8,9
 A recent study 
randomised patients to continue bevacizumab or to receive an EGFRI, after failure of first line 
chemotherapy plus bevacizumab. PFS and OS both favoured the continuation of bevacizumab.
10
 In 
sum these data suggest the possibility that initial bevacizumab may alter the biology of tumour cells, 
reducing their sensitivity to subsequent EGFRI.
11
 
Treatment and outcome data from large clinical registries may further inform our understanding of 
treatment sequencing, including whether prior bevacizumab impacts on the efficacy of later EGFRI. 
These analyses are of most value where treatment sequences or scenarios are not covered by 
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clinical trials, including analysis of patients who did and did not receive bevacizumab with first line 
chemotherapy and how this impacted the benefit of EGFRI therapy in later lines of treatment. Here 
we conduct this analysis of patients entered into the Treatment of Recurrent and Advanced 
Colorectal Cancer (TRACC) registry.
12
  In addition, where prior bevacizumab had been used, we 
analysed whether there was any impact of the time elapsed since ceasing bevacizumab. As there are 
multiple potential confounders in this analysis due to selection biases inherent to any registry, we 
further examined the known impact by tumour side given the differential impact of EGFRI based on 
primary tumour location. 
 
Methods 
Databases and Dataset 
The TRACC registry
 
captures data at the point of care including careful annotation of baseline patient 
and tumour characteristics, treatment(s) received and patient outcome
12
. Data from this multicentre 
registry, including institutions across Australia and Hong Kong, is de-identified and linked using the 
BIOGRID Australia software platform, prior to analysis.  
Chemotherapy drugs and biologics once reimbursed by the Australian Government under the 
Pharmaceutical Benefits Scheme (PBS) are freely available to patients. Prior to PBS approval 
treatment can only be accessed via clinical trials or patient access programs. We examined data from 
RAS wild-type patients diagnosed from July 2009 (when bevacizumab became PBS reimbursed  as a 
first line therapy). EGFRI use in second and later lines, as monotherapy or in combination with 
chemotherapy, became PBS reimbursed from September 2011.  From September 2015 first line use 
of EGFRI and second line use of bevacizumab became PBS reimbursed. We examined all patients 
diagnosed up until December 2016. 
We analysed data related to clinical and pathologic factors known to impact survival outcomes, 
including patient demographics, sites of metastatic disease, number of metastatic sites, side of 
primary tumour, Eastern Co-operative Oncology Group (ECOG) performance status, whether 
metastases were synchronous or metachronous, whether the primary was intact, and time to 
progression during first line treatment. Metachronous metastases were those defined as appearing 
at least 6 months after diagnosis of the primary tumour. A right sided primary was defined as any 
tumour proximal to the splenic flexure, whereas a left sided primary was a tumour of the splenic 
flexure or more distal colon or rectum.  
Patients who received an EGFRI in combination with chemotherapy or as a monotherapy in second 
or subsequent lines of treatment were included in the analysis. The specific antibody used 
(cetuximab or panitumumab) was recorded but data for both agents was combined given they are 
considered to have equivalent efficacy. Time to progression and overall survival data were calculated 
from the date of commencing the EGFRI.  
Initially we analysed outcomes based on whether or not patients had received any prior 
bevacizumab. The group that did receive prior bevacizumab was then further split by the time period 
between last bevacizumab dose and first dose of EGFRI (<6 months versus > 6 months). Analyses 
were then performed separately for patients with left and right sided primary tumours.  
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Statistical Analyses 
Progression free (PFS) and overall survival (OS), from the date the EGFRI was commenced, were 
calculated using the Kaplan Meier method. These were compared using the log rank test.  
Progression was judged by local clinicians and imaging was not centrally reviewed. 
All statistics were calculated using SAS Enterprise guide version 6.0 statistical software. 
Clinicopathologic differences between groups were assessed by the Chi-square and Wilcoxon rank 
sum tests for categorical and numerical variables, respectively.   
P values < 0.05 were considered significant. 
Ethical Approval 
The TRACC registry received ethics approval at each participating institution to conduct combined 
analyses of de-identified patient data. Patients were not required to sign informed consent. This 
specific project also received ethics approval (Number 2009.113 from the Melbourne Health Human 
Research Ethics Committee) 
 
Results 
Patients 
We identified 222 patients who had received an EGFRI in second or later lines of therapy, of whom 
170 (77%) had received prior bevacizumab (Figure 1). Of the 170 bevacizumab treated patients 159 
(92%) had received bevacizumab as part of first line therapy. Demographics, performance status, 
disease and treatment characteristics are summarized in Table 1. Generally, these were similar 
between the two groups, with the only significant difference being a longer time to progression on 
first line treatment in the group receiving bevacizumab.  Approximately 50% of patients in each 
group received chemotherapy, nearly always irinotecan based, in combination with the EGFRI. 
 
EGFRI efficacy 
Whether or not prior bevacizumab had been used did not impact PFS on EGFRI (Figure 2), median 
being 3.8 versus 4.2 months respectively, with a hazard ratio (HR) of 1.12; P=0.81. Furthermore, no 
PFS difference on EGFRI was seen when patients with left and right sided primary tumours were 
analysed separately (Figure 2 B and C). 
As the median time between ceasing bevacizumab and commencing the EGFRI was 6 months, this 
cut off was used to investigate any impact of the time period since last bevacizumab use on EGFRI 
efficacy. There were 87 and 83 patients in the < 6 month and > 6 month groups respectively. The 
characteristics of the patients in these 2 groups are shown in Table 2. Patients in the >6 month group 
had a longer time to first progression and fewer metastatic sites. Otherwise, the groups appear 
similar. PFS on EGFRI therapy is displayed in Figure 3. A significantly shorter PFS was seen for 
patients in whom the EGFRI was commenced 6 months or less after ceasing bevacizumab (median 
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PFS 3.2 versus 5.5 months; HR 1.37; P= 0.007). When analysed by primary tumour side, no difference 
was noted for left sided tumours (median PFS 4.2 V 5.5 months; HR 1.12. P=0.26), however in right 
sided tumours, PFS was significantly shorter with a time gap of less than 6 months (median PFS 2.2 V 
6 months; HR: 2.23. p= 0.01). When analysed by primary tumour side using a 12 month cut off, a 
similar, but non-significant, trend was seen. For left sided primaries, median PFS was 4.6 and 5.5 
months for  ≤ 12 and > 12 months respectively (p=0.32) and for right sided median PFS was 2.4 and 
6.2 months respectively (p=0.17). However, patient numbers were very small, with only 13 patients 
with a right sided primary having a greater than 12 month gap between bevacizumab and the EGFRI. 
OS data, calculated from the date of commencing the EGFRI, by prior bevacizumab, use is displayed 
in figure 4. No difference was seen. Median OS was 9.0 versus 9.2 months in the prior and no prior 
bevacizumab groups respectively, HR 1.12, P=0.48. 
Discussion 
A number of studies exploring the optimal use and sequencing of first line biologic therapy in RAS 
wild type metastatic colorectal cancer have produced unexpected results. The initial studies where 
first line bevacizumab and an EGFRI were combined, and given with chemotherapy, showed this 
combination to be detrimental.
13,14
 Therefore subsequent studies have explored optimal biologic 
sequencing. The FIRE-3 study compared first line FOLFIRI with either cetuximab or bevacizumab, 
with many patients, at investigator discretion, crossing to the alternate biologic in the second line. 
No difference in PFS was seen but there was a significant OS benefit in favour of first line cetuximab 
use.
3
 One possible explanation is that the initial biologic choice impacts later activity of the other 
biologic. Consistent with this hypothesis are the observed differences in 2
nd
 line PFS after patients 
crossed over to the alternate antibody in the FIRE3 study. Specifically, 2
nd
 line PFS favoured 
bevacizumab treated patients, suggesting the possibility that initial cetuximab either improved the 
efficacy of subsequent bevacizumab or initial bevacizumab reduced the subsequent efficacy of 
cetuximab.
7
 Here, using registry data, we have further explored the latter possibility, finding that the 
initial use of bevacizumab did not impact on later activity of an EGFRI therapy, suggesting clinicians 
can use EGFRI therapy after bevacizumab without concern that treatment efficacy will be 
compromised. However, a longer time gap (> 6 months) between bevacizumab and an EGFRI was 
associated with a longer PFS, a finding which was driven by patients with a right sided primary 
tumour. 
Our findings are consistent with those of other registry analyses which have shown no impact of 
prior bevacizumab on later EGFRI efficacy.
15,16
  In contrast, prospective trials investigating the 
optimal second line biologic, after first line bevacizumab, have produced conflicting results. The 
PRODIGE-18 study randomised 133 KRAS exon 2 wild type patients who had progressed after first 
line chemotherapy plus bevacizumab to the alternate chemotherapy backbone plus either 
cetuximab or bevacizumab. There was a trend for both PFS and OS in favour of continuing 
bevacizumab that was maintained even when analysing the subset of extended RAS and BRAF wild 
type patients.
10
 In this subgroup, median PFS and OS was 8.2 and 21.1 months versus 5.7 and 12.6 
months respectively (P value for PFS 0.1). An analysis of outcome by primary tumour side has not 
been presented to date.  However the suggestion of superiority for continuation of bevacizumab 
into second line versus switching to an EGFRI was not supported by 2 further studies from Japan 
(WJOG 6210G) and the US (SPIRRIT), both of which found no suggestion of a difference in outcome. 
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Again, to our knowledge, no analysis by primary tumour side is available from these 
studies
17,18
Another prospective, randomised phase 2 study conducted by the GISCAD group, in 
concordance with our findings, noted a significant interaction between side of primary tumour and 
the impact of time elapsed between bevacizumab and cetuximab on outcomes. Patients were 
randomised to FOLFOX then irinotecan/cetuximab, or the reverse sequence, after failure of first line 
FOLFIRI/bevacizumab.  A trend to superior PFS and OS was noted in the FOLFOX then 
cetuximab/irinotecan sequence, i.e. when a longer time gap between bevacizumab and cetuximab 
use had elapsed. This improvement was driven by patients with a right sided primary tumour.
19
  
When analysing these second line studies of EGFRI efficacy, it should be remembered that benefit as 
measured by PFS and OS may not correlate, as has been seen in first line treatment.
20
 In that setting 
greater depth of response influences post progression survival time. This phenomenon has not been 
adequately addressed in later line studies. 
International guidelines now recommend first line EGFRI use in combination with chemotherapy for 
left sided RAS wild type mCRC. Therefore any interaction between first line bevacizumab use and 
subsequent EGFRI efficacy will be most relevant for right sided primary tumours, perhaps raising the 
importance of the findings from our analysis.
21 
 
The specific sequence in which bevacizumab and EGFRI are used may impact treatment benefit due 
to a biologic impact on malignant cells and/or the microenvironment in response to treatment with 
one biologic, which then impacts the activity of the other. For example, in pre-clinical experiments, 
exposure to the anti-VEGF antibody  bevacizumab results in increased serum free VEGF levels which 
in turn activates VEGFR receptor 2 and Stat-3 leading to cellular resistance to the EGFRI cetuximab.
11
 
This might suggest a longer time gap between bevacizumab and cetuximab is preferable, which is 
supported by our findings and those of the GISCAD study in patients with metastases from right 
sided primary tumours.. 
The potential for a detrimental interaction between EGFRI and bevacizumab was first suggested by 
the findings of the CAIRO-2 and PACCE studies, which tested a combination of the two as part of first 
line treatment for mCRC.
13,14
 As well as an excess of adverse events with the biologic combination 
there was also an evident negative impact on survival outcomes.  This observation suggests that a 
separation in time between biologic use may be important, prompting us to explore the impact of 
the time between bevacizumab and an EGFRI. To our knowledge, this is the first study to report such 
data. We found no impact of timing on the efficacy of the EGFRI in left side tumours, a subset in 
which EGFRI are expected to be active. However, patients with a right sided primary receiving the 
EGFRI more than 6 months after bevacizumab had an increased PFS on EGFRI therapy. Given we are 
not expecting much activity of EGFRI therapy in patients with a right side primary,
22
 we would 
suggest this difference is mostly explained by confounding factors. For example, patients that 
received treatment after more than 6 months likely had more indolent biology and were destined to 
do better regardless of therapy. This is supported by the longer first line PFS and fewer metastatic 
sites noted in the > 6month group. In other words, the right sided patients living long enough to 
have treatment beyond 6 months represent a distinct subset with a superior survival outcome even 
when receiving an inactive therapy. Regardless of the explanation, this finding does highlight the 
challenges of defining the impact of the number of lines of treatment received.  For example, an 
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analysis of a large number of mCRC clinical trials found patients who had received all active 
chemotherapy drugs had the best outcome, 
23
 the authors interpreting this data to mean it was 
important to expose patients to as many drugs as possible. Our data suggest an alternative 
explanation for at least part of the observed survival impact: it is the patients who live long enough 
(due to indolent disease biology) to receive all the drugs that have the best outcome, even where 
they are treated with an inactive therapy such as an EGFRI in right colon cancers.  
A similar confounder might be expected in the left side tumours, but we did not observe a time 
based difference in this group.  This may reflect the known prognostic differences between left and 
right tumours, with left cancer patients having a more indolent biology, hence a more mixed 
population of left sided cancers may be included if a 6 month cut off is used. To further explore this 
we looked at a cut off of 12 months, but again found no efficacy difference in left patients.  
We acknowledge the limitations of our study, which was not prospective or randomised. Patients 
were treated at clinician discretion, with no pre-planned sequence of therapy. Some patients 
received EGFRI monotherapy, others combined with chemotherapy and we had insufficient numbers 
to further explore by these subsets. As such, biases may exist with undetected differences between 
the groups examined. Nonetheless, the registry data we analysed is very detailed and meticulously 
completed for each patient. The electronic database possesses an automated checking system to 
ensure validity of data as it is entered. A major strength of our registry is that it captures consecutive 
patients as they present to each institution, thus containing a true representation of the population 
with mCRC treated in daily practice, as opposed to randomised trials where eligibility criteria lead to 
considerable patient selection. 
In conclusion, whilst there remains considerable ongoing debate as to the optimal sequence of 
biologic therapy in metastatic colorectal cancer, our registry data does not support the hypothesis 
that first line bevacizumab use negatively impacts the subsequent efficacy of EGFRI therapy. There is 
an apparent relationship between the time between bevacizumab and EGFRI therapy and outcome 
in patients with right sided primary tumours, the reasons for which are unclear, but potentially due 
to confounding factors. 
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Figure 1. Consort diagram of patients.  
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Table 1. Patient and tumour characteristics 
 Prior Bevacizumab No Prior Bevacizumab P value 
                         N (%) 170 52  
                       Age 
                  < 70 
                  > 70 
 
126 (74%) 
44 (26%) 
 
39 (75%) 
13 (25%) 
 
0.90 
 
Sex 
- Male 
- Female 
 
109 (64%) 
61 (36%) 
 
33 (63%) 
19 (37%) 
 
0.93 
 
ECOG PS 
-0 
-1 
- ≥ 2 
 
87 (51%) 
73 (43%) 
10 (6%) 
 
26 (50%) 
20 (38%) 
6 (12%) 
 
 
0.37 
 
Chemotherapy with EGFR 
antibody 
 
 
 
23 (44%) 
 
 
All patients = 
2061
Systemic 
therapy = 1576
First line Bev (or 
later Bev prior 
to EGFRI) = 912
RAS Wt, EGFRI 
2nd line and 
beyond = 170
No first line Bev 
= 664
RAS Wt, EGFRI 
2nd line and 
beyond = 52
No systemic 
therapy = 485
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- None 
- Oxaliplatin based 
- Irinotecan based 
- Other 
85(50%) 
2 (1%) 
81 (48%) 
2 (1%) 
0 
28 (54%) 
1 (2%) 
0.71 
Primary tumour side 
- Right 
- Left 
- Unknown 
 
54 (32%) 
115 (68%) 
1 (1%) 
 
10 (19%) 
41 (79%) 
2 (2%) 
 
 
0.11 
Primary tumour resected 
- Yes 
- No 
 
124 (73%) 
46 (27%) 
 
37 (71%) 
15 (29%) 
 
0.80 
Synchronous 
Metachronous 
109 (64%) 
61 (36%) 
33 (63%) 
19 (37%) 
 
0.93 
 
Number of metastatic sites 
1 
2-3 
> 4 
 
83 (49%) 
76 (45%) 
11 (6%) 
 
26 (50%) 
24 (46%) 
2 (4%) 
 
0.78 
 
Metastatic sites 
- Peritoneum/Omentum 
- Liver 
- Lung 
 
43 (25%) 
115 (68%) 
42 (25%) 
 
11 (21%) 
39 (75%) 
15 (29%) 
 
0.59 
0.39 
0.59 
BRAF mutated 
Yes 
No 
unknown 
 
16 (9%) 
79 (47%) 
75 (44%) 
 
7 (14%) 
23 (44%) 
22 (42%) 
 
 
0.43 
Months to first line 
progression (median and 
9.1 (8.2 – 10.6) 6.9 (4.8 – 9.6) 0.02 
M
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95% CI)  
 
 
Table 2: Patient and tumour characteristics by time between ceasing bevacizumab and commencing 
EGFRI 
 
 <=6 months >6 months P value 
                    N (%) 87 83  
Age 
                         < 70 
                         > 70 
 
62 (71%) 
25 (29%) 
 
64 (77%) 
19 (23%) 
 
0.38 
 
Sex 
                           Male 
                           Female 
 
49 (56%) 
38 (44%) 
 
60 (72%) 
23 (28%) 
 
0.03 
 
ECOG PS 
0 
1 
 ≥ 2 
 
42 (48%) 
40 (46%) 
5 (6%) 
 
45 (54%) 
33 (40%) 
5 (6%) 
 
 
0.71 
 
 
Chemotherapy with EGFR 
antibody 
- None 
- Oxaliplatin based 
- Irinotecan based 
- Other 
 
 
40(46%) 
2 (2%) 
44 (51%) 
1 (1%) 
 
45 (54%) 
0 
37 (45%) 
1 (1%) 
 
 
 
0.42 
Primary tumour side 
- Right 
- Left 
 
32 (37%) 
54 (62%) 
 
22 (27%) 
61 (73%) 
 
 
0.20 
M
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PT
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- Unknown 1 (1%) 0 
Primary tumour resected 
 Yes 
 No 
 
62 (71%) 
25 (29%) 
 
62 (75%) 
21 (25%) 
 
0.61 
 
Synchronous 
 
Metachronous 
 
53 (61%) 
 
34 (39%) 
 
56 (67%) 
 
27 (33%) 
 
 
0.37 
 
Number of metastatic sites 
1 
2-3 
> 4 
 
33 (38%) 
47 (54%) 
7 (8%) 
 
50 (60%) 
29 (35%) 
4 (5%) 
 
 
0.01 
 
Metastatic sites 
- Peritoneum/Omentum 
- Liver 
- Lung 
 
24 (28%) 
63 (37%) 
24 (14%) 
 
19 (23%) 
52 (31%) 
18 (11%) 
 
0.48 
0.17 
0.37 
BRAF mutated 
Yes 
No 
unknown 
 
10 (12%) 
41 (47%) 
36 (41%) 
 
6 (7%) 
38 (46%) 
39 (47%) 
 
 
0.58 
Months to first line 
progression (median and 
95% CI) 
 
6.9 (5.7 – 8.1) 
 
11.8 (10.8 – 13.1) 
 
0.001 
 
 
Figure 2. PFS from commencing EGFRI by first line bevacizumab use. 2A = All patients 2B = Left 
primary 2C = Right primary. 
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Figure 3. PFS from commencing EGFRI by time since last bevacizumab administration. 3A = All 
patients 3B = Left primary 3C = Right primary.  
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Figure 4: Overall survival from starting anti EGFR antibody, by first line bevacizumab use. 
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